Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah.
Department of Obstetrics and Gynecology, Intermountain Healthcare, Salt Lake City, Utah.
Am J Perinatol. 2024 May;41(S 01):e456-e464. doi: 10.1055/a-1906-8919. Epub 2022 Jul 21.
Prostaglandins (PGs) use for cervical ripening with small for gestational age (SGA) fetuses is controversial since it remains uncertain if use increases the chance of cesarean delivery (CD). We aimed to assess the association between PG use for cervical ripening and mode of delivery between SGA and appropriate for gestational age (AGA) neonates.
Secondary analysis of the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b), a prospective observational cohort study of 10,038 nulliparas. We included women undergoing induction with nonanomalous fetuses in the cephalic presentation. Women with >2 cm cervical dilation or prior uterine scar were excluded. We assessed the association of PG use with CD among women with SGA and AGA neonates. SGA was defined as birth weight <10th percentile for gestational age and sex. Multivariable logistic regression was used to adjust for potential confounders and test for interaction. Secondary outcomes included adverse neonatal outcomes, indication for CD, maternal hemorrhage, and chorioamnionitis.
Among 2,353 women eligible, PGs were used in 54.8%, SGA occurred in 15.1%, and 35.0% had CD. The association between PG use and CD differed significantly (interaction = 0.018) for SGA versus AGA neonates; CD occurred more often in SGA neonates exposed to PGs than not (35 vs. 22%, = 0.009). PG use was not associated with CD among AGA neonates (36 vs. 36%, = 0.8). This effect remained significant when adjusting for body mass index, race/ethnicity, and cervical dilation. Among SGA neonates, CD for "nonreassuring fetal status" was similar between PG groups. Among SGA neonates, PG use was not associated with adverse neonatal outcomes or postpartum hemorrhage but had a higher rate of chorioamnionitis (7.0 vs. 2.1%, = 0.048).
PG use was associated with a higher rate of CD in SGA but not AGA neonates; however, further studies are needed before PG use is discouraged with SGA neonates.
· PGs are commonly used for cervical ripening.. · PG use was associated with increased risk of cesarean delivery in SGA neonates.. · PG use was not associated with adverse neonatal outcomes..
对于小胎龄儿(SGA),前列腺素(PGs)用于宫颈成熟存在争议,因为它仍然不确定使用 PG 是否会增加剖宫产(CD)的机会。我们旨在评估 PG 用于宫颈成熟与 SGA 和适当胎龄(AGA)新生儿之间分娩方式的关系。
对 Nulliparous Pregnancy Outcomes Study:Monitoring Mothers-to-Be(nuMoM2b)的二次分析,这是一项对 10038 名初产妇的前瞻性观察队列研究。我们纳入了经阴道分娩的非畸形胎儿的产妇。排除了宫颈扩张大于 2cm 或有子宫瘢痕的妇女。我们评估了 PG 在 SGA 和 AGA 新生儿中与 CD 的关系。SGA 定义为出生体重低于胎龄和性别的第 10 个百分位数。多变量逻辑回归用于调整潜在的混杂因素并检验交互作用。次要结局包括新生儿不良结局、CD 指征、产妇出血和绒毛膜羊膜炎。
在 2353 名符合条件的妇女中,54.8%使用了 PG,15.1%发生了 SGA,35.0%发生了 CD。PG 使用与 CD 的关系在 SGA 与 AGA 新生儿之间差异显著(交互作用 = 0.018);PG 暴露的 SGA 新生儿中 CD 更常见(35%比 22%, = 0.009)。在 AGA 新生儿中,PG 使用与 CD 无关(36%比 36%, = 0.8)。当调整体重指数、种族/民族和宫颈扩张时,这种影响仍然显著。在 SGA 新生儿中,PG 组之间“非胎儿状态不良”的 CD 相似。在 SGA 新生儿中,PG 使用与新生儿不良结局或产后出血无关,但绒毛膜羊膜炎发生率较高(7.0%比 2.1%, = 0.048)。
PG 在 SGA 但不是 AGA 新生儿中与更高的 CD 发生率相关;然而,在不鼓励 SGA 新生儿使用 PG 之前,还需要进一步的研究。
· PGs 常用于宫颈成熟。
· PG 使用与 SGA 新生儿的 CD 风险增加相关。
· PG 使用与新生儿不良结局无关。